In preclinical models and patient samples of ovarian and breast cancer, including ascite metastases and in situ carcinomas, reduced DNA damage-induced nuclear RAD51 is positively associated with BRCA1 or BRCA2 gene defects and patient response to PARPi [65, 66]. This evidence concerns the gene BRCA2 and cancer.